2023-12-11 06:01:35 ET
Regeneron Pharmaceuticals ( NASDAQ: REGN ) on Sunday presented updated trial data for its bispecific lymphoma antibody, odronextamab, in patients with relapsed/refractory (R/R) follicular lymphoma (FL).
Odronextamab is currently under regulatory review for the treatment of R/R FL and diffuse large B-cell lymphoma by the U.S. Food and Drug Administration, with a target action date of March 31, 2024, as well as by the European Medicines Agency.
Longer-term data from the pivotal Phase 2 trial continued to confirm high rates of durable responses in patients with R/R FL. Updated results showed an 80% objective response rate and a 73% complete response, with a 23-month median duration of response and 24-month median duration of complete response.
Median progression-free survival in complete responders was 28 months (95% confidence interval: 20 months to not estimable) and 21 months for all patients (95% confidence interval: 17 to 28 months)?. However, median overall survival was not reached (95% confidence interval: 32 months to NE).?
In addition, oral presentation showcased overall maintenance of patient-reported outcomes from baseline to 50 weeks during investigational odronextamab treatment.
More on Regeneron Pharmaceuticals
- Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 35th Annual Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (REGN) Presents at Truist Securities BioPharma Symposium (Transcript)
- Regeneron lifts complete remission in trial for multiple myeloma candidate
- Replimune shares crash as skin cancer candidate fails trial
For further details see:
Regeneron lymphoma therapy shows high response rate in ongoing trial